Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Inmune Bio Inc (INMB)
NASDAQ:INMB
Inmune Bio (INMB) Stock Price & Analysis
272 Followers
INMB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.50 - $14.74
Previous Close$11.13
Volume124.76K
Average Volume (3M)112.74K
Market Cap
$229.23M
Enterprise Value$194.53M
Total Cash (Recent Filing)$35.85M
Total Debt (Recent Filing)$10.44M
Price to Earnings (P/E)-6.7
Beta1.10
Next Earnings
Aug 06, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.67
Shares Outstanding18,026,473
10 Day Avg. Volume231,721
30 Day Avg. Volume112,741
Standard Deviation0.27
R-Squared0.14
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)10.04
Price to Sales (P/S)1294.42
Price to Cash Flow (P/CF)-15.40
P/FCF Ratio0.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.26K
Enterprise Value/Gross Profit1.26K
Enterprise Value/Ebitda-12.31
Forecast
1Y Price Target
$19.67Price Target Upside70.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Inmune Bio News
Bulls Say, Bears Say
Bulls Say
Drug Development ProgressINmune announced positive data from a recent study of XPro treatment in moderate to severe Alzheimer's disease patients, showing significant improvements in electroencephalography (EEG) assessments.
Financial StabilityINmune remains well-capitalized with $41.8M in cash reported at the end of 3Q23, which should provide runway into 2025.
Regulatory MilestoneFDA's lifting of the clinical hold on INMB's lead program allows continuation of international trials and advancing the overall development program.
Bears Say
Data RequirementsFDA has now requested 18 and 24 month data using similar metrics.
Regulatory ChallengesThe P2 trial remains on full clinical hold in the US pending information on long-term potency.
Trial Progress ConcernsWording on timing of phase 2 clinical trial of XPro for early Alzheimer's disease changed in the latest press release, signaling potential uncertainty.
---
Ownership Overview
36.84% Insiders
3.45% Mutual Funds
3.39% Other Institutional Investors
56.32% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
INMB FAQ
What was Inmune Bio Inc’s price range in the past 12 months?
Inmune Bio Inc lowest stock price was $6.50 and its highest was $14.74 in the past 12 months.
What is Inmune Bio Inc’s market cap?
Currently, no data Available
When is Inmune Bio Inc’s upcoming earnings report date?
Inmune Bio Inc’s upcoming earnings report date is Aug 06, 2024 which is in 94 days.
How were Inmune Bio Inc’s earnings last quarter?
Currently, no data Available
Is Inmune Bio Inc overvalued?
According to Wall Street analysts Inmune Bio Inc’s price is currently Undervalued.
Does Inmune Bio Inc pay dividends?
Inmune Bio Inc does not currently pay dividends.
What is Inmune Bio Inc’s EPS estimate?
Inmune Bio Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Inmune Bio Inc have?
Inmune Bio Inc has 19,760,984 shares outstanding.
What happened to Inmune Bio Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Inmune Bio Inc?
Currently, no hedge funds are holding shares in INMB
---
Inmune Bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.67 (70.01% Upside)
$19.67 (70.01% Upside)
Blogger Sentiment
Bearish
INMB Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
44.92%
12-Months-Change
Fundamentals
Return on Equity
-61.09%
Trailing 12-Months
Asset Growth
-30.31%
Trailing 12-Months
Company Description
Inmune Bio Inc
Inmune Bio, Inc. is a clinical stage biotechnology company, which develops immunotherapies that reprogram a patient's innate immune system to allow the immune system to fight cancer. Its products include INKMUNE and INB03. The company was founded by Mark Lowdell in September 2015 and is headquartered in La Jolla, CA.
---
INMB Earnings Call
Q4 2024
0:00 / 0:00
---
INMB Stock 12 Months Forecast
Average Price Target
$19.67
▲(70.01% Upside)
Technical Analysis
Bioxcel Therapeutics
―
Ovid Therapeutics
―
Revance Therapeutics
―
Ultragenyx Pharmaceutical
―
Best Analysts Covering INMB
1 Year
1 Year Success Rate
9/14 ratings generated profit
1 Year Average Return
+17.83%
reiterated a buy rating 4 days ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 64.29% of your transactions generating a profit, with an average return of +17.83% per trade.
---